Kyntra Bio News and Activities

Kyntra Bio is a company listed under the stock ticker KYNB (US).

Acquisition, funding and merger involving Kyntra Bio.

• The new name of Fibrogen is Kyntra Bio. (posted on January 8 2026).
• Kyntra Bio is now listed under ticker KYNB. (posted on January 8 2026).

View the org chart displaying its 14 main executives

Most searched biographies at Kyntra Bio

• Thane Wettig, Chief Executive Officer and Director
• Jeffrey Edwards, Director
• James Schoeneck, Chairman of the Board

Create your alert
to follow the executive moves at Kyntra Bio.

Kyntra Bio has 2,428 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (posted on July 15 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Kyntra Bio

• FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined | FibroGen, Inc.
• FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer | FibroGen, Inc.
• FibroGen to Present at Upcoming Investor Conferences | FibroGen, Inc.
• FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy | FibroGen, Inc.
• FibroGen Reports Second Quarter 2020 Financial Results | FibroGen, Inc.
• FibroGen Announces New Appointments to its Board of Directors | FibroGen, Inc.
• FibroGen to Report Second Quarter 2020 Financial Results | FibroGen, Inc.
• FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19 | FibroGen, Inc.
• FibroGen Appoints Thane Wettig as Chief Commercial Officer | FibroGen, Inc.
• FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress | FibroGen, Inc.
• View more press releases Close

Social media about Kyntra Bio

• Kyntra Bio on Wikipedia, Google News & Yahoo Finance
• Kyntra Bio on LinkedIn, X (Twitter) & YouTube